Join me in this Fast Focus to discuss the latest trends in personalized medicine and health technology assessment, based on recent views shared by Mike Drummond.
In this video, I reflect on Mike's comments and the potential of gene therapy, the challenges of cost-effectiveness, and the intriguing shift in data availability for new drug approvals.
He shares insights on managing uncertainty in healthcare decision-making and adapting to fast-track approval processes.
#SyenzaTeam#PersonalizedMedicine#GeneTherapy, #CostEffectiveness,
Hey there guys, let's chat about some developments in personalized medicine. Mike Drummond shared his views in a recent presentation by colleagues at Oxford Population Health, University of Oxford. Uh, we're seeing some pretty cool stuff happening with gene therapy and individual treatments, but you know, it's not all smooth sailing and we've definitely got some interesting challenges to tackle soon. And actually scientifically from the from the gene therapy and whatever, I mean, it's getting close to the point where you could determine, you know, more on an individual basis and what would be the best treatment for I think then it's going to get into a question of well, how expensive or cheap are these going to be? I mean, I'm addicted lot won't be very cost effective if if they've been persisting high prices. So, uh, you know, I, I think, I think that's more of the challenge, but, but the other thing is, which is interesting observation on my recently is that if you think of most branches of science, we have better data today than we had like 10 years ago. In approving new medicines, that's not true. We have less data than we had ten years ago because the actions of the licensing authorities to make drugs available early. Not by through these fast track mechanisms. So we the the health economists and the HOA people are working with less data than they had before. And so we've had to figure out ways of dealing with that, you know, argue how'd you manage that uncertainty? One way, of course, is to have these processes whereby you give a preliminary appraise, preliminary approval and then revisit when there's more evidence available. But I mean, I think that's a trend that's not going to be reversed. Unless we suddenly find that people are dying because they've ended up having inappropriate therapy through early approval. But it's not going to stop. So hey, we're dealing with Let's data these days, but that's not stopping us. We're getting more creative, finding new ways to handle this uncertainty. It's a bit of a balancing act like Mike mentioned, but that's what makes us feel so exciting, right? We always adapting and always moving forward. What are your views though? Drop a comment below, we'd love to hear from you. Thank you for joining me for this fast focus and see you in the next video. Take care.
Following the 2024 SIIA Cell & Gene Therapy Forum, COEUS' Matt Paul put some post-conference thoughts on paper. So, we're excited to share Matt's latest article that addresses some of the most pressing challenges faced by insurers in managing high-cost therapies.
The article, "Performance Guarantees: Leveraging Technology to Enable Insights into Reimbursement Opportunities," explores how innovative platforms like COEBRA™ can transform the landscape of #reimbursement and #patientaccess.
#ValueBasedContracting#HealthcareInnovation#Reinsurers#1COEUS
You can read the full piece here: https://lnkd.in/eqVPUUXn
Having attended SIIA's Cell & Gene Therapy Forum for the 2nd year, the conversation around correlating outcomes with therapeutic use is only increasing. In fact, value-based assessment coupled with a warranty is standard if manufacturers want DAY ONE coverage. COEBRA adjudicates more CGTx VBA-Warranty programs than any other platform and is a testament to the years of experience our team has in building & operationalizing VBAs at scale.
#1Coeus#celltherapy#genetherapy#CGTweekly#valuebasedcontracting
Following the 2024 SIIA Cell & Gene Therapy Forum, COEUS' Matt Paul put some post-conference thoughts on paper. So, we're excited to share Matt's latest article that addresses some of the most pressing challenges faced by insurers in managing high-cost therapies.
The article, "Performance Guarantees: Leveraging Technology to Enable Insights into Reimbursement Opportunities," explores how innovative platforms like COEBRA™ can transform the landscape of #reimbursement and #patientaccess.
#ValueBasedContracting#HealthcareInnovation#Reinsurers#1COEUS
You can read the full piece here: https://lnkd.in/eqVPUUXn
At the Economist Impact’s Cell and Gene Therapy (CGT) 2024 Summit, experts from across the industry discussed numerous topics and challenges in the introduction of CGTs:
📌 Regulatory
📌 Manufacturing and supply chain
📌 Clinical and scientific
📌 Commercial
See the attached white paper capturing important themes and takeaways from the summit, including regulatory changes and new delivery models, the need to keep conversations and practices focused on patients, and how to structure clinical trials, gather real world evidence and streamline manufacturing to help improve access to treatment.
#CellAndGeneTherapy#CGT#Innovation#biopharma#EconomistImpact#curiousmindsHannah Kurth
People first, then Tech | Demystifying technology, to improve people's lives and change the world | MES/MOM & IT/OT Convergence | Cybersecurity | Problem solver and Innovator #Digital Transformation#Innovation
Curious how to ease connectivity and scalability in your gene therapy manufacturing process? Hear from our collegue, Dan Updyke, as he sat down with Phacilitate at Advanced Therapies Week to address the key challenges facing the industry and how digitilazation and automation can help. Watch the interview here:
https://lnkd.in/ecuKn8Xr
Navigating the complexities of rAAV vector manufacturing can be daunting for small and mid-sized biotech companies venturing into the exciting world of gene therapy. Ensuring consistent quality and optimizing production processes are paramount for success.
Read the blog to learn how advanced analytics can be transformative in achieving these goals: https://lnkd.in/d5YggbDV#Expertise#Blog#AdvancedAnalytics#rAAV#GeneTherapy
At the Economist Impact’s Cell and Gene Therapy (CGT) 2024 Summit, experts from across the industry discussed numerous topics and challenges in the introduction of CGTs:
📌 Regulatory
📌 Manufacturing and supply chain
📌 Clinical and scientific
📌 Commercial
See the attached white paper capturing important themes and takeaways from the summit, including regulatory changes and new delivery models, the need to keep conversations and practices focused on patients, and how to structure clinical trials, gather real world evidence and streamline manufacturing to help improve access to treatment.
#CellAndGeneTherapy#CGT#Innovation#biopharma#EconomistImpact#curiousminds
I solve the unsolvable for biotech CTOs, turning critical bioprocess development challenges into biologics manufacturing breakthroughs | Strategic Advisor | CMC Development | Project Management
Are you finding the path to commercializing cell and gene therapies complex and uncertain?
Join us as we explore this intricate landscape with our guest, Wajiha Ali.
Highlights:
- Uncover the hurdles of patient referrals and manufacturing regulations, amplifying the complexity of these therapies.
- Explore essential commercialization strategies and infrastructure needs while balancing innovation with necessity.
-Learn about navigating regulatory scrutiny and stakeholder management for safer, more accessible therapies.
What do you believe are the keys to facilitating the journey from scientific breakthroughs to real-world applications?
#cellculture#processdevelopment#bioprocessing#celltherapymanufacturing#cellandgenetherapy#leadbiotech
